Just a moment, the page is loading...
The Supported Studies Programme

For the latest updates on GSK’s response to COVID-19, please click here.

Specialty



Timelines






[Nucala ISS/SCS Committee. Last updated in June 2022.]
GSK call for research proposals of relevance to disease understanding and impact of mepolizumab in two disease areas:
• Severe eosinophilic asthma (SEA)
• Hypereosinophilic syndrome (HES)

Applications are invited in the following areas:
• Impact of mepolizumab on prevention of organ damage and disease progression
• Composite outcomes with real-world use of mepolizumab, such as remission
• Patient identification biomarkers of those at risk of worse long-term clinical outcomes
• Non-eosinophilic biological effects of interleukin 5 (IL-5)
• CNS assessment of mechanisms of mepolizumab in promoting “well-being”

[Sotrovimab ISS/SCS Committee. Last updated in June 2022.]
• Data to support the identification of individuals at highest risk of disease progression, despite vaccination/booster program, and the identification of biomarkers to prioritize patient
groups that would gain most benefit from sotrovimab
• Data to support the role of sotrovimab in patients with post-COVID syndrome (Long COVID) or persistent SARS-COV-2 infection (including sequelae and relative to other treatments)
• Burden of Long COVID and long-term impact of sotrovimab (including sequelae and relative to other treatments)
• Pre-clinical, clinical and real-world data on the effectiveness of sotrovimab in early treatment of high-risk patient groups including: a) relative to other monoclonal antibodies and
oral anti-virals; or b) activity against SARS-CoV-2 variants
• Data on the long-term protective effect of sotrovimab when given as early treatment (including relative to other treatments)
• Data to support the use of other COVID-19 therapeutics pre-, peri-, or post-treatment with sotrovimab and with vaccination
• Activity of sotrovimab against viral mutants in context of other mono / combo monoclonal antibodies (planned clinical trial and non-clinical analysis)

[Daprodustat ISS/SCS Committee. Last updated in May 2022.]
• Clinical practices and behaviours related to the management of anemia of CKD
• Healthcare resource utilisation related to anemia of CKD
• Burden and impact of untreated anemia of CKD across different geographies or related to differential healthcare access, including underserved populations
• Novel technologies to improve patient care and/or the patient experience in the management of anemia of CKD
• Effectiveness of Daprodustat in subgroups of special interest
Including patients not reaching Hb target, inflamed patients, diabetic patients, anephritic patients, home dialysis, peritoneal dialysis, transplant
• New indications (other than anemia of CKD), where Daprodustat could benefit patients

[Otilimab ISS/SCS Committee. Last updated in Jan 2022.]
GSK is not accepting new supported study submissions related to otilimab COVID at this time. Any accepted submissions, where funding has been confirmed, will be progressed as planned. Please contact your local GSK office if you require further information. We will publish updates at this site shortly. Thank you.

[Belimumab ISS/SCS Committee. Last updated in May 2021.]
GSK is not accepting new supported study submissions related to Belimumab (Benlysta) at this time. Any accepted submissions, where funding has been confirmed, will be progressed as planned. Please contact your local GSK office if you require further information. We will publish updates at this site should things change. Thank you.

Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.



© 2001-2022 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.